amustaline/谷胱甘肽病原体灭活红细胞在寨卡病毒输血传播风险区的随机双盲对照3期试验方案
RedeS研究是一项3期、前瞻性、多中心、随机、双盲、活性对照、平行设计试验,评估amustaline/谷胱甘肽病原体灭活红细胞(PR-RBCs)与常规红细胞相比,在需要急性或反复输血支持患者中的安全性和有效性。研究计划纳入600-800例受试者进行总体安全性分析,主要安全终点为输血相关治疗中出现的不良事件和治疗中出现的PR-RBCs特异性抗体,主要疗效终点为基线无出血受试者的血红蛋白增量(经输注Hb克数校正)。
要点
- amustaline/GSH PR-RBCs旨在灭活红细胞中的病原体和白细胞。
- 主要疗效终点为基线无出血患者的血红蛋白增量非劣效性。
- 计划纳入600-800例,其中约140例反复输血者进入6个月延伸期。
核心结论
- RedeS研究将表征amustaline/GSH PR-RBCs的安全性,并设计证明其血红蛋白增量非劣效于常规红细胞。
研究设计与样本
- 3期、前瞻性、多中心、随机、双盲、活性对照、平行设计研究,含6个月延伸期。
- 计划纳入600-800例受试者进行总体安全性分析,包括约140例反复输血受试者(含最多30例接受三次红细胞置换者)。
- 受试者按研究中心、基线出血状态和是否参与延伸期分层。
主要发现
- 主要安全终点为末次研究输血后28天内与研究红细胞输血相关的治疗中出现不良事件(TEAEs)患者比例,以及确认对PR-RBCs特异性的治疗中出现抗体患者比例。
- 主要疗效终点为基线无出血受试者的血红蛋白(Hb)增量,经输注Hb克数校正并在多次输血中平均。
- 352例可评估输血的非出血受试者(每组176例)时,研究有80%把握度证明非劣效性,非劣效界值为Hb增量治疗差异不超过对照组均值的15%,假设对照组变异系数为50%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Red blood cell (RBC) transfusion may be lifesaving, however transfusion-transmitted infections (TTI) and transfusion-associated graft-versus-host disease (TA-GVHD) still pose a threat despite current donor selection and testing requirements. Amustaline (S-303)/glutathione (GSH) pathogen reduction (PR) is designed to inactivate infectious microbes and leukocytes in RBCs. The RedeS study evaluates the safety and efficacy of amustaline/GSH PR-RBCs compared to conventional RBCs in a broad spectrum of patients requiring acute and/or repeated RBC transfusion support. METHODS: RedeS is a Phase 3, prospective, multi-center, randomized, double-blind, active-controlled, parallel-design study, with a 6-month extension option to evaluate patients requiring repeated transfusions including red cell exchange (RCE). Eligible subjects will be stratified according to site, baseline bleeding status and participation in the extension period. The study arms include a transfusion period of 28-days for anemia with any bleeding or non-bleeding patients or a 28-day + 6-month extension for non-bleeding patients with chronic anemia requiring repeated simple transfusions, or for patients with sickle cell disease (SCD) expected to receive three RCE procedures. The study will seek to enroll 600-800 subjects in the overall safety analysis, including ~ 140 repeatedly-transfused subjects in the 6-month extension including up to 30 subjects receiving three RCE procedures. The primary safety endpoints are the proportion of patients with any treatment-emergent adverse events (TEAEs) related to study RBC transfusion through 28 days after the last study transfusion, and the proportion of patients with treatment-emergent antibodies with confirmed specificity to PR-RBCs. The primary efficacy endpoint is the hemoglobin (Hb) increment in subjects who are non-bleeding at baseline, adjusted for the grams of Hb transfused and averaged over multiple transfusions. With 352 evaluable transfused non-bleeding subjects (176 per treatment group) from either arm, the study will have 80% power to demonstrate non-inferiority, defined as a Hb increment treatment difference of no more than 15% of the Control group mean, assuming a Control arm coefficient of variation of 50%. DISCUSSION: RedeS will characterize the safety of amustaline/GSH PR-RBCs and is designed to demonstrate the non-inferiority of PR-RBCs to conventional RBCs with respect to Hb increment, a common pragmatic clinical assessment of RBC transfusion effectiveness. TRIAL REGISTRATION: A Randomized, Double-Blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for red blood cells in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections (RedeS Study). CLINICALTRIALS: gov ID NCT03037164. Registered on 27 January 2017 at https://clinicaltrials.gov/ct2/show/NCT03037164 .
引用
- Ayala EFC, Colon LV, Aydinok Y, et al. A randomized, double-blind, controlled, parallel group study with amustaline/glutathione pathogen reduced red blood cells in regions at potential risk for Zika virus transfusion-transmitted infections (RedeS Study)-protocol for a phase 3 clinical trial. Trials. 2026. PMID: 42186075. doi:10.1186/s13063-026-09808-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。